1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends

The Future of Biosimilars 2016

  • July 2016
  • Firstword Pharma
Report ID: 3090982


Table of Contents

Development activity is surging as the focus shifts to commercialisation. How will the market evolve?
The race to commercialise biosimilars is on. What will it take to create a thriving market? Will payers see real cost savings? Will developers make money? What will drive uptake—and what will slow it down?
This must-read report explores how these issues are likely to play out, with first-hand insight from patient groups, physicians, lawyers, and stakeholders from originator and biosimilar companies.
You’ll learn about developers’ market access strategies, originators’ efforts to keep them at bay, key drivers for adoption, and the impact of unresolved regulatory and policy questions. Development is surging, attitudes are improving, and key decisions are imminent. Find out where the market is headed.
“…biosimilars are perfectly poised to come in as part of the solution to the issue of increased pharmaceutical spending.”
- Christine Simmon – SVP & Executive Director, Biosimilars Council, GPhA

“…there's no one size fits all. You really have to look at the market by channel, by therapy area, by country, and then make the right call about how to commercialise your product depending on those factors.”
- Carol Lynch – Global Head of Biopharmaceuticals, Sandoz

Understand the Forces Shaping the Biosimilars Market

Commercialisation: Differentiation may be the key success factor for biosimilars. Discover the strategies manufacturers are using to gain an edge over branded drugs and rival biosimilars.
Regulation: As commercial concerns take centre stage, two important regulatory questions remain unanswered. Find out what they are, and how they’ll affect market access.
Litigation: A defining characteristic of the US market, litigation is now on the rise in Europe too. Learn which actions—defensive and offensive—will have the greatest impact.
Adoption: A decade of experience with biosimilars in Europe has revealed the biggest drivers of adoption. Find out what they are, and what countervailing forces may be slowing down uptake.
Plus, a full market analysis: The number of biosimilars programmes has grown by nearly 15% since last year. Get a breakdown of the current landscape by class and by molecule

Answering Key Questions

Critical mass: A huge number of biosimilars will be ready for regulatory review in the next 12-18 months. Can regulators keep up? What will it mean for the market if they can’t?
No word on interchangeability in the US: What are developers doing to prepare for the (hopefully) imminent release of FDA guidelines? Just how important is an interchangeability designation?
The role of data: How are clinical data requirements for biosimilar applications likely to change? Will analytical data play a bigger role?
Who will switch? How has a decade of experience with biosimilars in Europe shaped attitudes toward switching both treatment-naïve and established patients to biosimilars?
Getting crowded: How will the market handle multiple biosimilars of the same reference drugs? What factors will influence key access and reimbursement decisions?
Emerging opportunities: How do regulatory standards in developing economies compare to those in developed ones? How will they affect future opportunities for developers?
Looking ahead: Events in the next 12-18 months could define the decade to come. How will the market evolve? Who will the key players be, and which reference drugs will they target next?

Expert Contributors
FirstWord interviewed 12 physicians, legal professionals, industry stakeholders, and patient representatives for this report. All interviewees either have direct experience in the development or commercialisation of biosimilars or are considered experts in their respective fields.

Dominic Adair. Partner, Bristows LLP, London, UK
Paul Calvo. Director, Biotechnology/Chemical Group, Sterne, Kessler, Goldstein and Fox, Washington, DC, US
Paul Cornes. UK-based Oncologist
Clare Jacklin. Director of External Affairs, National Rheumatoid Arthritis Society (NRAS), UK
James Kent. Clinical Lead Pharmacist, Southend University Hospital NHS Trust, Westcliff-on-Sea, UK
Patrick Lucy. Founder and Chief Business Officer, Pfenex Inc., San Diego, California, US
Carol Lynch. Global Head of Biopharmaceuticals, Sandoz
Steinar Madsen. Medical Director, the Norwegian Medicines Agency
Christine Simmon. Senior Vice President of Policy & Strategic Alliances, Generic Pharmaceutical Association (GPhA), Washington, DC, US
Martyn G. Smith. Senior member of the Global Biologics Strategy team, F. Hoffmann-La Roche, Switzerland
Florian Strohmaier. Director of Regulatory Affairs & Quality Management, Formycon AG
Anonymous US biosimilars expert. Working for a US-based biotechnology firm

Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:


The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Erythropoietin (EPO) Drugs Market Analysis By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application, And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • May 2017
  • by Grand View Research

The global erythropoietin (EPO) drugs market is expected to reach USD 17.4 billion by 2025, according to a new report by Grand View Research, Inc. Rising incidence of chronic diseases such as CKD and cance ...

Global Biosimilars Market

  • $ 4250
  • Industry report
  • July 2017
  • by Mordor Intelligence LLP

The global biosimilar market was estimated to be USD XX million in 2016 and is expected to reach USD XX million by 2021, witnessing a CAGR of XX% during the forecast period. Biosimilar is a biological ...

Japan Biosimilars – A start of Authorized Biosimilar Era? - Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market!

  • $ 4000
  • Industry report
  • August 2017
  • by MP Advisors

Major JP Innovator vs. Early entrant Mid size Japanese companies- TA focus approach – A Win Win Game! In this report, we attempt to evaluate key upcoming opportunity for Japan BS market, its competitive ...


Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.